Wells Fargo & Company Edgewise Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 23,241 shares of EWTX stock, worth $845,507. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,241
Previous 20,431
13.75%
Holding current value
$845,507
Previous $372,000
12.37%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding EWTX
# of Institutions
147Shares Held
96.8MCall Options Held
45.7KPut Options Held
5.3K-
Orbimed Advisors LLC San Diego, CA15MShares$546 Million6.52% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$324 Million2.42% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$219 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$212 Million1.4% of portfolio
-
Novo Holdings Hellerup, G75.55MShares$202 Million10.36% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $2.3B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...